Policy Impact

CHeRP research contributed to national or local health care policy decisions in the following areas:

  • Adoption of pneumococcal vaccine for children in the U.S.
  • Adoption of pertussis vaccine for adolescents and adults in the U.S.
  • Funding of a unique program of the Global Alliance on Vaccines and Immunizations to accelerate the adoption of pneumococcal vaccine for children in developing countries
  • Funding of a unique program of the Global Alliance on Vaccines and Immunizations to accelerate the adoption of pneumococcal vaccine for children in developing countries
  • A change in the recommendations for the use of measles-mumps-rubella-varicella vaccine to improve safety for young children
  • A change in the Vaccine Information Statement on the risk for febrile seizures in young children following concomitant influenza and PCV13 vaccination
  • Expanded use of Federally Qualified Health Center designation by state immunization programs to minimize out-of-pocket costs of vaccination for underinsured children
  • Supported activities by CDC, FDA and HHS to conduct surveillance for adverse events following H1N1 vaccines in the U.S. and to support ongoing decision making regarding benefit-risk balance
  • Service on national committees including the Institute of Medicine and participation on numerous working groups convened by the Centers for Disease Control and Prevention, Society for Healthcare Epidemiology of America, and Advisory Committee on Immunization Practice
  • Invitations to present nationally to the Maryland Health Quality and Cost Council, Vermont Oxford Network, Centers for Disease Control and Prevention, National Vaccine Advisory Committee, Advisory Committee on Immunization Practices, and the World Health Organization’s Global Advisory Committee on Vaccine Safety